Erythropoietin Drugs Have Gained Immense Popularity in the Healthcare Sector — Explore

Erythropoietin (EPO) is a glycoprotein hormone that stimulates the erythropoiesis and is naturally produced by and in perisinusoidal cells in the liver and by interstitial fibroblasts in the the kidneys. EPO is highly glycosylated, and its carbohydrate portion contributes two-fifth portion of its molecular weight. EPO production is activated by hypoxia and is regulated via an oxygen-sensitive feedback loop. Erythropoietin plays an important role in stimulating red blood cell production in the bone marrow and works in the brain’s response to neuronal injury.

According to a report published by Allied Market Research, the global erythropoietin drugs market size is registered to reach $14.4 billion with a considerable CAGR from 2021 to 2028. The Asia-Pacific region is currently holding the largest market share and is expected to manifest the highest growth rate, owing to presence of key market players in this region. On top of that, as India and China are having the major markets for erythropoietin biosimilar, majority of originator companies for erythropoietin are focusing on the Asia-pacific region. Manufacturers in this region can afford to launch biosimilar versions of EPO at much lesser price than innovator products.

Rise in prevalence of cancer, HIV, anemia, and kidney diseases, surge in level of awareness about the benefits of EPO therapeutics, and commercialization for erythropoietin biosimilars drive the growth of the global erythropoietin drugs market. However, longer duration of treatment, unaffordability of therapeutics, and adverse amount of side effects hinder the market growth. On the contrary, the commercialization of darbepoetin alfa biosimilar and achieving economies of scale across developed regions are expected to open lucrative opportunities for the market players in the future.

Covid-19 scenario:

The outbreak of the COVID-19 pandemic led to have a slight negative impact on the global erythropoietin drugs market, especially in the initial period. This is attributed to disruptions in the workflows of the healthcare sector and temporary closure of drug manufacturing facilities as well as sub-domains of healthcare. On the other hand, rise in demand for erythropoietin drugs during the pandemic boosted the market growth.

• The outbreak of Covid-19 disrupted the workflow in the healthcare sector as the rapid spread of coronavirus forced several industries to shut down temporarily.
• However, the pandemic had a positive effect on the demand for medical services including erythropoietin.
• As erythropoietin is used to treat anemia and can be effective against Covid-19, which boosted its demand. Moreover, it has anti-ischemic, anti-apoptotic, and regenerative effects in several tissues such as kidney, lungs, nervous system, retina, and pancreas. Thus, it can be used to treat critically ill patients.

Download Sample Report at: https://www.alliedmarketresearch.com/request-sample/59

Growth of the market is driven by rise in number of treatment cycles for chemotherapy and increase in number cases including cancer,HIV, kidney diseases, and anemia.

Moreover, factors such as surge in incidences of end stage renal diseases (dialysis) and increase in number of treatment cycles for chemotherapy have driven the demand for erythropoietin drugs to a great extent. The erythropoiesis-stimulating agents (ESAs), intravenous iron and blood transfusions are now being widely used for the treatment of anemia in patients with chronic renal failure and cancer patients with chemotherapy-induced anemia. Here, it is worth mentioning that with the increase in trends of commercialization for erythropoietin biosimilars, favorable government regulations, readily available reimbursements, and rise in awareness regarding advantages of EPO therapeutics, the demand for erythropoietin drugs is likely to surge exponentially in the coming years.

Author’s Bio — Suchita Gupta is an explorer, musician and content writer. While pursuing MBA, she found that nothing satisfies her more than writing on miscellaneous domains. She is a writer by day, and a reader by night. Besides, she can be found entertaining her audience on social media platforms. Find her on LinkedIn & Instagram.